Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 759 citations

Medicine, Oncology, Pharmacology +13

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel et al. · Journal of Clinical Oncology · 2007 · 733 citations

Medicine, Oncology, Pharmacology +17

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman et al. · Journal of Clinical Oncology · 2002 · 688 citations

Medicine, Oncology, Pharmacokinetics +14

Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

Francis J. Major, John A. Blessing, Steven G. Silverberg et al. · Cancer · 1993 · 665 citations · Full text

Medicine, Gynecology, Oncology +14

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2009 · 573 citations · Full text

Medicine, Oncology, Cancer Pharmacology +15